Home > Insider Trading > Filing (0001209191-14-009857)

Filing Details

Accession Number:: 0001209191-14-009857
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-12 18:13:24
Reporting Period:: 2014-02-12

Filing Date:: 2014-02-12
Accepted Time:: 2014-02-12 18:13:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1105533	Argos Therapeutics Inc	ARGS	Pharmaceutical Preparations (2834)	562110007

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1543084	Sander Deventer Van	C/O Forbion Capital Partners Gooimeer 2-35 1411 Dc Naarden P7		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-12	984,840	$0.00	984,840	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2014-02-12	1,428,888	$0.00	2,413,728	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2014-02-12	36,416	$8.00	2,450,144	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2014-02-12	984,840	$0.00	984,840	$0.00
Common Stock	Series E Preferred Stock	Disposition	2014-02-12	1,428,888	$0.00	1,428,888	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series D Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series D Preferred Stock has no expiration date.
Each share of Series E Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series E Preferred Stock has no expiration date.
Represents shares held of record by Cooperatieve AAC LS U.A.
Consists of (i) 247,847 shares held by Cooperatieve AAC LS U.A. and (ii) 1,181041 shares held by Forbion Co-Investment II Cooperatief U.A.
Consists of (i) 21,701 shares purchased by Cooperatieve AAC LS U.A. and (ii) 14,715 shares purchased by Forbion Co-Investment II Cooperatief U.A.
Forbion 1 Management B.V., the director of Cooperatieve AAC LS U.A has voting and investment power over the shares held by Cooperatieve AAC LS U.A, which are exercised through Forbion 1 Management B.V.'s investment committee, consisting of L.P.A. Bergstein, H. A. Slootweg, M. A. van Osch, G. J. Mulder and the Reporting Person. None of the members of the investment committee has individual voting and investment power with respect to such shares, and the members disclaim beneficial ownership of such shares except to the extent of their pecuniary interests therein.
Forbion 1 Co- II Management B.V., the director of Forbion Co-Investment II Cooperatief U.A., has voting and investment power over the shares held by Forbion Co-Investment II Cooperatief U.A., which are exercised through Forbion 1 Co II Management B.V.'s investment committee, consisting of L.P.A. Bergstein, H. A. Slootweg, M. A. van Osch, G. J. Mulder and the Reporting Person. None of the members of the investment committee has individual voting and investment power with respect to such shares, and the members disclaim beneficial ownership of such shares except to the extent of their pecuniary interests therein.